Alterity Therapeutics Limited
PRNAF
$0.01
$0.00133.33%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 1.23M | 1.20M | 523.20K | 538.00K | 698.00K |
| Total Revenue | 1.23M | 1.20M | 523.20K | 538.00K | 698.00K |
| Cost of Revenue | 20.50K | 20.10K | 20.70K | 21.30K | 38.70K |
| Gross Profit | 1.21M | 1.18M | 502.50K | 516.70K | 659.40K |
| SG&A Expenses | 695.30K | 680.90K | 1.08M | 1.11M | 890.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 9.80K | 9.60K | 18.40K | 18.90K | 500.00 |
| Total Operating Expenses | 3.51M | 3.44M | 2.98M | 3.07M | 4.98M |
| Operating Income | -2.28M | -2.23M | -2.46M | -2.53M | -4.28M |
| Income Before Tax | -1.57M | -1.54M | -2.34M | -2.40M | -4.14M |
| Income Tax Expenses | 21.80K | 21.30K | -- | -- | 15.20K |
| Earnings from Continuing Operations | -1.59M | -1.56M | -2.34M | -2.40M | -4.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.59M | -1.56M | -2.34M | -2.40M | -4.16M |
| EBIT | -2.28M | -2.23M | -2.46M | -2.53M | -4.28M |
| EBITDA | -2.28M | -2.23M | -2.45M | -2.52M | -4.27M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 7.48B | 7.48B | 5.31B | 5.31B | 4.79B |
| Average Diluted Shares Outstanding | 7.48B | 7.48B | 5.31B | 5.31B | 4.79B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |